BREAKING NEWS

BioNTech to price coronavirus vaccine below market rates

By REUTERS

NOVEMBER 10, 2020 12:26

BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.

Speaking at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would reflect the financial risks that its private-sector investors have incurred.

"We’ve tried to pursue a balanced approach that recognizes that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we're in and with the goal to insure broad-based access around the world," Richardson said at the FT event.

"I expect there to be differential pricing in certain regions of the world," he added, declining to elaborate on the different price tags.

New York's Bryant Park holiday market in flames

By JERUSALEM POST STAFF

12/27/2024 07:34 PM

US: Likely Azerbaijan Airlines downed by Russian air defense

By REUTERS

12/27/2024 06:58 PM

Turkey to allow pro-Kurdish party to visit jailed militant leader

By REUTERS

12/27/2024 06:55 PM

Bashar al-Assad's uncle Rifaat flew from Beirut to Dubai

By REUTERS